Zimmer Biomet Holdings, Inc. with ticker code (ZBH) have now 22 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 150 and 105 calculating the average target price we see 133.68. Now with the previous closing price of 122.35 this now indicates there is a potential upside of 9.3%. The day 50 moving average is 125.48 and the 200 moving average now moves to 115.75. The company has a market capitalisation of $25,949m. You can visit the company’s website by visiting: https://www.zimmerbiomet.com
The potential market cap would be $28,352m based on the market concensus.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
